STOCKS TELEGRAPH

Tag: Trevena stock

  • How Has The Trevena (TRVN) Stock Declined 13% In Extended Trades?

    How Has The Trevena (TRVN) Stock Declined 13% In Extended Trades?

    In after-hours trading, shares of Trevena Inc. (TRVN) were down -12.76% on Friday. The stock closed the previous trading session up 2.62% or $0.05 at $1.96. The stock fluctuated between $1.93 and $2.00 throughout the day. A total of 22.49 million shares were exchanged, more than TRVN’s 50-day volume of 3.41 million as well as its year-to-date volume of 3.46 million.

    The TRVN stock has lost 13.95 percent in the past 12 months, and in the last week the stock has gained 2.62%. A total of -20.33 % has been lost by TRVN stock over the last six months, and 7.10 % has been gained over the last three months. The TRVN stock price is down by 8.41% this year. In response to the reinstatement of patient recruitment for one of its studies, TRVN stock rose.

    In what study did TRVN take part?

    Trevena specializes in developing and commercializing treatments for patients with disorders of the central nervous system. A TRVN product, OLINVYK (oliceridine) injection, is approved in the United States for the treatment of adults who have acute pain severe enough to require intravenous opioid analgesic therapy and for whom alternative treatments are ineffective.

    TRRVN’s novel pipeline includes four investigational drug candidates that are the result of Nobel Prize-winning research. TRV027 is used to treat acute respiratory distress syndrome, abnormal blood clotting, and COVID-19-related symptoms; TRV734 treats opioid use disorder; TRV250 treats migraines and TRV045 treats epilepsy.

    Trevena announced recently that NIDA has reopened enrollment for its TRV734 prospective patient study, which tests the new mu opioid receptor selective agonist.

    • As part of TRVN’s ongoing collaboration with NIDA, TRV734 is being evaluated as potential maintenance therapy for opioid use disorder (OUD).
    • As a result of the global COVID-19 pandemic in March 2020, TRVN has paused its study.
    • In spite of COVID-19, opioid use disorder (OUD) is still a public health emergency.
    • TRVN believes it is important to continue developing effective treatments for patients suffering from opioid addiction.
    • By resuming their TRV734 study, NIDA emphasizes the unmet need for treatments for OUD, as TRV734 may be an effective treatment option with improved tolerability.
    • NIH and TRVN will join forces to explore a number of its pipeline assets as part of this collaboration.
    • This study aims to enroll approximately 50 opioid-dependent people undergoing stable methadone maintenance therapy in a double-blind, placebo- and positive-controlled study.
    • Using the Clinical Opioid Withdrawal Scale, this study will also evaluate whether TRVN’s TRV734 suppresses withdrawal symptoms.

    How the TRVN candidate will be evaluated?

    TRV734 will be the third Trevena (TRVN) investigational drug product being studied by NIDA. According to the Subjective Opioid Withdrawal Scale, the primary outcome is a reduction in withdrawal symptoms through TRVN drug. Additionally, secondary outcomes will include an assessment of safety, tolerability, and measure of changes in neurocognitive function of TRVN candidate.

  • Why Is Trevena (TRVN) Stock Up in Pre-Hour Trades?

    Why Is Trevena (TRVN) Stock Up in Pre-Hour Trades?

    The shares of Trevena Inc. (TRVN) were up 6.44% in premarket trading at $2.15. TRVN stock closed at $2.02 yesterday, down -8.18% or $0.18. TRVN stock fluctuated between $2.01 and $2.18 on the day.

    TRVN stock traded at 2.63 million shares, less than the company’s average daily volume of 3.22 million during its 50-day period. On the resumption of patient recruitment by the NIH, TRVN stock jumped.

    Why were patients recruited?

    Trevena focuses on the development and commercialization of innovative drugs for patients with diseases related to the central nervous system (CNS). OLINVYK (oliceridine) injection is TRVN’s only U.S.-approved product. As an opioid analgesic, OLINVYK has been indicated in the treatment of acute pain in adults who are unable to be managed using alternative treatments.

    As announced by Trevena today, NIDA is once again recruiting patients for TRV734, the Company’s novel mu-opioid receptor selective agonist.

    • TRVN has been collaborating with NIDA to evaluate TRV734 as a potential treatment for opioid use disorder (OUD).
    • The TRVN study was halted in March 2020 due to the global COVID-19 pandemic.
    • Despite COVID-19, opioid use disorder is an urgent public health issue that must be addressed.
    • In order to meet the needs of opioid addicted individuals, it is important to continue to develop effective treatments.

    TRN plans to go further:

    NIDA’s willingness to re-open the TRV734 study, which may present a treatment option that is effective and more tolerable than the current recommendations, demonstrates the unmet need for OUD medicines. Trevena (TRVN) will leverage this collaboration to explore several pipeline assets in the NIH.

  • What changed for these 31 stocks in Pre Market Session

    What changed for these 31 stocks in Pre Market Session

    Xenetic Biosciences Inc. (XBIO) stock plunged -15.46% to $2.68 in the pre-market trading following the company’s announcement of $6.0 million registered direct offering priced at-the-market under Nasdaq Rules. The most recent rating by Maxim Group, on January 08, 2020, is a Buy.
    Curis Inc. (CRIS), a Biotechnology company, dropped about -5.72% at $7.25 in pre-market trading Thursday after declaring the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million.
    ZW Data Action Technologies Inc. (CNET) lost over -11.33% at $1.8 in pre-market trading Thursday December 10, 2020 after reporting the official opening of its first live streaming platform in Guangzhou, China.
    Genius Brands International Inc. (GNUS) is up more than 9.74% at $1.69 in pre-market hours Thursday December 10, 2020. The firm recently revealed that it will be presenting at the 13th Annual LD Micro investor conference on Tuesday, December 15th at 10:00 a.m. PST / 1:00 p.m. EST. The stock had dropped over -4.35% to $1.54 in the last trading session.
    Rocket Companies Inc. (RKT), a Mortgage Finance company, rose about 3.09% at $21.71 in pre-market trading Thursday following the release of Clear HOI platform from its subsidiary to mortgage lenders nationwide.
    Intec Pharma Ltd (NTEC) stock moved down -7.76 percent to $4.28 in the pre-market trading. Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma.
    Atossa Therapeutics Inc. (ATOS) gained over 2.31% at $0.8919 in pre-market trading Thursday December 10, 2020 after revealing cannabinoid research collaboration with GW Pharma.
    Nano Dimension Ltd. (NNDM) is up more than 2.25% at $6.82 in pre-market hours Thursday December 10, 2020 following the declaration from the company that it has closed the registered direct offering of 30,000,000 of the Company’s American Depositary Shares at a price of $6.00 per ADS. The stock had dropped over -6.06% to $6.67 in the last trading session.
    Before the trading started on December 10, 2020, Sorrento Therapeutics Inc. (SRNE) is down -2.44% to reach $8.01 following the FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). It has been trading in a 52-week range of $1.55 to $19.39.
    Genetic Technologies Limited (GENE) stock plunged -9.17% to $4.06 in the pre-market trading.
    Greenwich LifeSciences Inc. (GLSI) grew over 46.76% at $83.8 in pre-market trading today after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.
    Lipocine Inc. (LPCN), a Biotechnology company, dropped about -5.3% at $1.25 in pre-market trading Thursday after announcing that the U.S. Food and Drug Administration has granted tentative approval to TLANDO.
    SELLAS Life Sciences Group Inc. (SLS) stock moved up 51.8 percent to $9.7 in the pre-market trading. The biotechnology firm recently revealed exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China.
    Francesca’s Holdings Corporation (NASDAQ: FRAN) shares are trading down -10.68% at $2.51 at the time of writing after receiving court approval of “First Day” motions to support ongoing operations. Company’s 52-week ranged between $1.70 to $19.91. Analysts have a consensus price target of $2.50.
    Oncternal Therapeutics Inc. (ONCT) tumbled over -27.78% at $4.55 in pre-market trading today after announcing that the firm increased its previously declared bought deal to $75.0 million.
    Gran Tierra Energy Inc. (GTE) is down more than -2.83% at $0.35 in pre-market hours Thursday December 10, 2020. The company recently declared a financial update and the Company’s 2021 capital budget and production guidance. The stock had dropped over -5.68% to $0.36 in the last trading session.
    Before the trading started on December 10, 2020, Fisker Inc. (FSR) is down -4.04% to reach $16.15. The firm recently confirmed that it has signed agreements with Cox Automotive U.K. (“Cox”) and Rivus Fleet Solutions for delivery, servicing, fleet management and reselling programs in the United Kingdom. It has been trading in a 52-week range of $8.70 to $23.63.
    Immutep Limited (IMMP) stock soared 89.35% to $4.09 in the pre-market trading after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. The most recent rating by B. Riley FBR, on September 28, 2018, is a Buy.
    Remark Holdings Inc. (MARK), a Internet Content & Information company, rose about 3.09% at $1.67 in pre-market trading Thursday after reporting that Remark’s KanKan AI business successfully released its edge computing systems, the S and T Series Smart Boxes.
    Baidu Inc. (BIDU) gained over 2.42% at $155.26 in pre-market trading Thursday December 10, 2020. The firm recently released new intelligent vehicle solutions for automakers and several high-end intelligent driving products during the second Apollo Ecosystem Conference.
    Before the trading started on December 10, 2020, Editas Medicine Inc. (EDIT) is up 9.13% to reach $55.2 after reporting submission of IND application for EDIT-301 with the FDA. It has been trading in a 52-week range of $14.01 to $43.65.
    Artelo Biosciences Inc. (ARTL) stock plunged -2.47% to $0.66 in the pre-market trading. The healthcare firm recently declared that it has filed a composition of matter patent application directed to a new solid dosage formulation, including its method of use, with the UK Patent Office.
    AquaBounty Technologies Inc. (NASDAQ: AQB) shares are trading down -17.07% at $7.19 at the time of writing following the selection of Innovasea as the Recirculating Aquaculture Systems (“RAS”) technology provider for its planned 10,000 metric ton farm. Company’s 52-week ranged between $1.52 to $11.40. Analysts have a consensus price target of $5.
    Pluristem Therapeutics Inc. (PSTI) lost over -5.57% at $6.61 in pre-market trading Thursday December 10, 2020 after declaring DMC recommendation following interim analysis of its phase III CLI study.
    Before the trading started on December 10, 2020, Veru Inc. (VERU) is up 25.96% to reach $4.9 after reporting that it has exclusively licensed worldwide rights to enobosarm, a late-stage oral novel androgen receptor (AR) targeting agent for the treatment of endocrine resistant ER+ HER2- metastatic breast cancer. It has been trading in a 52-week range of $2.10 to $4.74.
    Uranium Energy Corp. (AMEX: UEC) shares are trading down -4.32% at $1.33 at the time of writing. Company’s 52-week ranged between $0.35 to $1.59. Analysts have a consensus price target of $1.50.
    Boxlight Corporation (BOXL), a Communication Equipment company, rose about 7.23% at $1.78 in pre-market trading Thursday. The firm recently confirmed that they are the recipients of three THE Journal’s Best New EdTech Product Awards.
    Regulus Therapeutics Inc. (RGLS) stock moved up 19.34 percent to $1.07 in the pre-market trading. The company lately announced closing of $19.4 million private placement of equity.
    Before the trading started on December 10, 2020, Sea Limited (SE) is down -3.3% to reach $196.0 after reporting that it proposes to offer 11,000,000 American Depositary Shares, each representing one Class A ordinary share of the Company, in an underwritten public offering. It has been trading in a 52-week range of $35.61 to $207.51.
    Barclays PLC (NYSE: BCS) shares are trading down -3.85% at $7.5 at the time of writing. The firm recently revealed the launch of BARX Book for Equities, a new single-dealer platform developed in partnership with Nasdaq (Nasdaq: NDAQ). Company’s 52-week ranged between $3.41 to $10.22.
    Qualigen Therapeutics Inc. (QLGN) stock moved up 13.85 percent to $4.44 in the pre-market trading. The company recently announced board member Amy Broidrick as EVP, Chief Strategy Officer and named Sidney Emery, Jr. to its board.